HAVE ANY QUESTIONS? CLICK HERE
Le Programme d'Investissements d'Avenir, France Relance et la Région Pays de la Loire nous soutiennent
- Biomatlante News
Le Programme d'Investissements d'Avenir, France Relance et la Région Pays de la Loire nous soutiennent dans le développement d'une nouvelle génération de substituts osseux synthétiques.
Dr. Cyril d'Arros made a fire presentation at ESB2023
- Biomatlante News
Dr. Cyril d'Arros selected to make a fire presentation at the 33rd Annual Conference of the European Society for Biomaterials (ESB)
EZ Cure™ Resorbable Collagen Membrane MDR approved
- Biomatlante News
Biomatlante - Advanced Medical Solutions Group, is immensely proud to announce the MDR* approval for the EZ Cure™ Resorbable Collagen Membrane – Guided bone Regeneration.
AMS strengthens its senior leadership team with appointment of industry leader Chris Locke to newly created role of Chief Technology Officer
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, is pleased to announce that on 9 August, Chris Locke will join the Group’s senior management team as Chief Technology Officer.
Covid-19 pandemic : Biomatlante continues its activity
- Biomatlante News
Nantes, France, March 18, 2020
Dear Partner,
In this new context of fighting the spread of the Covid-19 virus, Biomatlante has adapted its organization in order to ensure the continuity of its services to support you in your activity.
Congratulations from Biomatlante team!
BIOMATLANTE joins the AMS Group
- Biomatlante News
Biomatlante is very pleased to announce the acquisition of 100% of its shares by Advanced Medical Solutions Group plc (London Alternative Investment Market: AMS).
Biomatlante: a new step towards the MDR
- Biomatlante News
Just after BSI last January, TÜV Süd Product Service GmbH is now the second Notified Body designated to issue CE Marking certifications under the European Medical Devices Regulation (MDR).
Biomatlante receives MDSAP Accreditation
- Biomatlante News
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the obtention of the MDSAP* accreditation on the new ISO 13485:2016 Certificate.
BIOMATLANTE announces the appointment of its new CEO
- Biomatlante News
Julien Dert named as new CEO of Biomatlante, Chantal Gobin continues as Chairman of the Board
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the appointment of its new CEO, Julien Dert, being effective on February 1st, 2019.
Clinical Performance of hydrogel- bioceramic Putty for Bone Regeneration in maxillofacial surgery
- Biomatlante News
The article shows the valorization of results of a non interventional clinical study of 78 patients with the product In’Oss™ in association with a collagen resorbable membrane in maxillofacial surgery. The safety and efficacy of In’Oss has been demonstrated, as well as the performance of EZ Cure membrane associated to it.
Variation of bone forming ability with the physicochemical properties of calcium phosphate bone substitutes
- Biomatlante News
Six commercially available CaP bone substitutes (Bio-Oss, Actifuse, Bi-Ostetic, MBCP, Vitoss and chronOs) as well as two tricalcium phosphate (TCP) ceramics with either a micron-scale (TCP-B) or submicronscale (TCP-S) surface structure are characterized and their bone forming potential is evaluated in a canine ectopic implantation model.
MBCP+™, the adapted matrix for tissue engineering
- Biomatlante News
After the success of the European program REBORNE (FP7) focused on safety and efficacy of the Biomatlante matrix combined with autologous bone marrow expanded mesenchymal stem cells (MSC), MBCP+™, made from our well-known MBCP Technology, was confirmed as the adapted matrix for tissue engineering and chosen for 2 new European research programs (H2020): MAXIBONE and ORTHOUNION.
Coordinated by INSERM (Institut National de la Santé et de la Recherche Médicale) and with the support of the E.U., the REBORNE Program sought to establish the feasibility, relevance and efficacy of the association of MBCP+™*, a synthetic bone graft manufactured by Biomatlante made from MBCP™ Technology, and Mesenchymal Stem Cells (MSCs)1.
Introduction: Bone is the most transplanted tissue in human with about 1 million procedures annually in Europe. Autologous bone grafting is the gold standard in bone regeneration but it requires a second surgery, is limited in quantity and often associated with painful complications. Synthetic calcium phosphate biomaterial in association with mesenchymal stem cells may be a potent alternative to autologous bone grafting.
Biomatlante’s Timeline: 20 Years of Innovative Expertise
- Biomatlante News
Emmanuel Macron: we represent the medicine of future
- Biomatlante News
Emmanuel Macron, minister of Economy, met May 18, 2015 in Nantes, with the actors mobilized for the reindustrialization project “the Industry of the Future”, new array of industrial strategy. On its way to play a mainly role in the phase II of New Industrial France (NFI), this project aims to modernize the industrial tool and transform its business model by digital.
